Thats not medicine - thats bureaucracy
The SUSTAIN-6 trial for semaglutide (3,297 patients, median 2.1 years), LEADER trial for liraglutide (9,340 patients, median 3.8 years), and REWIND trial for dulaglutide (9,901 patients, median 5.4 years) all included comprehensive adverse event monitoring
Some thoughts... This new study is consistent with studies showing NMN, an NAD booster & SIRT1 activator, improves bone mass in miceThis paper summarizes the evidence that GLP1RA drugs benefits boneNMN has been shown in mice to improve healing of broken bones..And this one on SIRT1's benefits on bone:But be aware that these drugs can have negative side effects on the kidney, muscle and even increase the chances of sudden blindness!Another side effect of GLP-1RA is muscle loss
AMG 133 PK profile in mice and obese cynomolgus monkeys AMG 133 exhibits persistent PK properties after a single intravenous (i.v.) injection of 5 mg kg 1 in mice (Fig
Both peptides show published activity across rodent and cell-culture tissue-repair models without binding a single canonical receptor, distinguishing the blend from receptor-targeted compounds